Canaccord Genuity Reiterates Buy on Anthera Pharmaceuticals (ANTH)

By admin | 6 years ago

Anthera Pharmaceuticals (NASDAQ: ANTH)‘s stock had its “buy” rating reiterated by investment analysts at Canaccord Genuity in a note issued to investors on Monday.

Shares of Anthera Pharmaceuticals traded up 0.56% during mid-day trading on Monday, hitting $1.78. Anthera Pharmaceuticals has a 52 week low of $1.44 and a 52 week high of $9.08. The company’s market cap is $73.0 million.

ANTH has been the subject of a number of other recent research reports. Analysts at MLV & Co initiated coverage on shares of Anthera Pharmaceuticals in a research note to investors on Thursday, April 26th. They set a “buy” rating and a $4.50 price target on the stock. Separately, analysts at Mizuho initiated coverage on shares of Anthera Pharmaceuticals in a research note to investors on Thursday, April 26th. They set a “buy” rating and a $4.50 price target on the stock. Finally, analysts at Auriga downgraded shares of Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note to investors on Friday, March 16th.

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.

About the author